Could a gentler antibiotic beat gonorrhea without fueling superbugs?
NCT ID NCT07631364
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares a single intravenous dose of temocillin to the standard ceftriaxone shot for treating gonorrhea. The goal is to see if temocillin works just as well while having less impact on the gut's healthy bacteria, which can help prevent the rise of drug-resistant germs. The study plans to enroll 360 adults with asymptomatic gonorrhea and check for cure at day 21.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- temocillin (NEGABAN®) given as a single 2 g intravenous dose
- What this could lead to
- If it works, this could offer a safer antibiotic option for gonorrhea that is less likely to promote drug-resistant bacteria in the gut.
- What could go wrong
- This is a single-dose IV antibiotic study; it may not be as effective as the standard shot, and results may not apply to all populations or strains.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEISSERIA GONORRHOEAE (NG) INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service des maladies infectieuses et tropicales, Hôpital Saint-Antoine, GHU AP-HP Sorbonne Université
Paris, 75012, France